Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies
Authors:
- Natalie F. McMynNMNatalie F. McMyn
- Joseph VarrialeJVJoseph Varriale
- Hanna W. S. WuHWHanna W. S. Wu
- Vivek HariharanVHVivek Hariharan
- Milica MoskovljevicMMMilica Moskovljevic
- Toong Seng TanTTToong Seng Tan
- Jun LaiJLJun Lai
- Anushka SinghalASAnushka Singhal
- Kenneth LynnKLKenneth Lynn
- Karam MounzerKMKaram Mounzer
- Pablo TebasPTPablo Tebas
- Luis J. MontanerLMLuis J. Montaner
Open Access
- 29 July 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Abstract
Antiretroviral therapy (ART) prevents HIV-1 replication but does not eliminate the latent reservoir, the source of viral rebound if treatment is stopped. Autologous neutralizing antibodies (aNAbs) can block in vitro outgrowth of a subset of reservoir viruses and therefore potentially affect viral rebound upon ART interruption. We investigated aNAbs in 31 people with HIV-1 (PWH) on ART. Participants fell into two groups based on a high or low fraction of aNAb-resistant reservoir isolates, with most isolates being aNAb-resistant (IC50 >100 μg/ml). Time on uninterrupted ART was associated with higher aNAb resistance. However, pharmacodynamic analysis predicted that many isolates would be partially inhibited at physiologic IgG concentrations, to the same degree as by single antiretroviral drugs. Steep dose-response curve slopes, an indication of cooperativity, were observed for the rare isolates that were very strongly inhibited (>5 logs) by aNAbs. Resistance to aNAbs was not fully explained by declining in aNAb titers and may be driven partially by ADCC-mediated elimination of infected cells carrying aNAb-sensitive viruses over long time intervals, leaving only aNAb-resistant viruses which can contribute to viral rebound.Keywords
Funding Information
- NIH Martin Delaney Collaboratories for HIV Cure Research (UM1AI164556, UM1AI164570, UM1AI164560)
- Howard Hughes Medical Institute (N/A)
- Robert I. Jacobs Fund of The Philadelphia Foundation (N/A)
- Herbert Kean, M.D., Family Professorship (N/A)
This publication has 125 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latencyNature Medicine, 1995
- Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptaseJournal of Virology, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous seraAIDS, 1990
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984